-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
Rapid Communication
(3173) Views (1702) Full article downloads
Authors: Terry Golombick, Terry Diamond
Published Date March 2008
Volume 2008:2(1) Pages 161 - 163
DOI: http://dx.doi.org/10.2147/BTT.S2514
Terry Golombick, Terry Diamond
Department of Endocrinology, St George Hospital, Kogarah, Australia
Abstract: Plasma cell dyscrasias, most commonly associated with paraproteinemia, are a diverse group of diseases. Monoclonal gammopathy of undefined significance (MGUS) can precede multiple myeloma, a progressive neoplastic disease. MGUS occurs in association with a variety of other diseases and currently no treatment is recommended but rather “watchful waiting”. Given that the size of the M-protein is a risk factor for disease progression, early intervention with the aim of reducing the paraprotein load would provide an innovative therapeutic tool. Preliminary results from our pilot study show a drop of between 5% and 30% serum paraprotein in patients taking curcumin compared with patients on placebo. Curcumin is a diferuloylmethane present in extracts of the rhizome of the Curcuma longa plant. As a natural product, this has exciting potential in the treatment of plasma cell dyscrasias.
Keywords: plasma cell dyscrasias, MGUS, myeloma, curcumin, paraproteinemia
Other articles by Dr Terry Golombick
Readers of this article also read:
α-L-iduronidase therapy for mucopolysaccharidosis type I
Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy
Therapeutic vaccines for malignant brain tumors
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Abatacept in difficult-to-treat juvenile idiopathic arthritis
Periosteoplasty for covering gingival recessions: Clinical results
Erratum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




